Johns Hopkins Medicine/Wikimedia CommonsRoland Griffths/psilocybin mushrooms
Roland Griffiths is a Johns Hopkins University professor, researcher and expert in the field of pharmacology. He is best known for his research into the beneficial effects psilocybin on cancer patients.
He began his research into psilocybin and other psychedelics when he began meditation. He is a proponent of the connection between science, spirituality and mysticism. Griffiths is continuing his psilocybin research and hopes to complete larger scale trials to produce conclusive data. Preliminary data shows promising results.
Griffiths is also the founder and director of the Johns Hopkins Center on Psychedelic and Consciousness Research. He appears on 60 Minutes in an episode that airs on CBS at 7:30 p.m. EST Sunday, October 13, 2019.
Heres what you need to know:
Studies into the effects of psilocybin predated the Controlled Substances Act, which President Richard Nixon signed into law in 1970. Psilocybin was also used as a substance for healing and spiritual connection in ancient times. The Controlled Substances Act labeled psilocybin a Schedule 1 controlled substance, meaning it has high potential for abuse and does not serve a legitimate medical purpose. Griffiths acknowledges there are risks associated with psilocybin, but his preliminary data shows that there are benefits which he believes outweigh the risks when it is used in a controlled environment.
Researchers conducted studies before the Controlled Substances Act, but their studies required further research. The law effectively prevented studies into whether psilocybin did, in fact, have any medical benefits. His research into the effects of psilocybin began in 1999 after he received FDA approval to conduct studies, he said on a TED Talk in 2015.
His profile on the Johns Hopkins Center on Psychedelic and Consciousness Research says:
In 1999 he initiated a research program investigating the effects of the classic psychedelic psilocybin that includes studies in healthy volunteers, in beginning and long-term meditators, and in religious leaders. Therapeutic studies with psilocybin include treatment of psychological distress in cancer patients, treatment of cigarette smoking cessation, and psilocybin treatment of major depression. Other studies have examined the effects of salvinorin A, dextromethorphan, and ketamine which produce altered states of consciousness having some similarities to psilocybin. Drug interaction studies and brain imaging studies (fMRI and PET) are examining pharmacological and neural mechanisms of action. The Hopkins laboratory has also conducted a series of internet survey studies characterizing various psychedelic experiences including those associated with acute and enduring adverse effects, mystical-type effects, entity and God-encounter experiences, and alleged positive changes in mental health, including decreases in depression and anxiety, decreases in substance abuse, and reductions in death anxiety.
Griffiths founded the Johns Hopkins Center on Psychedelic and Consciousness Research and continues to serve as its director. He is also a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, according to his Johns Hopkins University profile.
Roland Griffiths, Ph.D., is a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, and founding Director of the Johns Hopkins Center on Psychedelic and Consciousness Research, the profile says. His principal research focus in both clinical and preclinical laboratories has been on the behavioral and subjective effects of mood-altering drugs.
He is also a member of the Expert Advisory Panel on Drug Dependence for the World Health Organization, and he has been a consultant to the National Institutes of Health and to pharmaceutical companies regarding the development of new psychotropic drugs. He has also conducted research into sedative-hypnotics, caffeine and other mood-altering drugs.
Griffiths has written more than 380 journal articles and book chapters, his profile says. He holds a Ph.D. from the University of Minnesota in Minneapolis, Minnesota, which he obtained in 1972, and he has a bachelor of science degree from Occidental College in California, which he earned in 1968, according to a separate Johns Hopkins University profile.
Roland Griffiths said his interest in research into the beneficial properties of psychedelic drugs began when he started a meditation practice, he said in a 2009 interview with Mulidisciplinary Association for Psychedelic Studies journal. He was trained as a psychopharmacologist, with training in both experimental psychology and pharmacology.
He said in the 2009 interview:
About fifteen years ago, I took up a meditation practice that opened up a spiritual window for me, and made me very curious about the nature of mystical experience and spiritual transformation. It also prompted an existential question for me about the meaningfulness of my own research program in drug abuse pharmacology. On reflecting about the history of psychopharmacology and the claims that had been made about the classical hallucinogens occasioning mystical and spiritual experience, I became intrigued about whether I could turn the direction of some of my research program toward addressing those kinds of questions. Through a confluence of interactions and introductions, I first met Robert Jesse of the Council of Spiritual Practices, and he introduced me to Bill Richards, who had a long history of working with these compounds from the 1960s and 70s. We decided that we would undertake a research project characterizing the effects of psilocybin.
His foray into meditation was a life-changing experience for him, which shifted his outlook on life, he said in a 2015 TED Talk.
Roland Griffiths discussed his research into the effects of psilocybin on a TED Talk in 2015, framing the discussion as a connection between science and spirituality or mysticism. You can watch the full TED Talk here.
Its like trying to mix oil and water. Most people assume that science and spirituality dont play well together, but its not true. Einstein said that the most beautiful and profound emotion we can experience is the sensation of the mystical. He said its the source of all true science, Griffiths said.
Griffiths discussed details about his studies, which showed promising results in studies on healthy participants, cancer patients and smokers. He noted his data is preliminary and the drug must be used in a controlled environment to reduce risks. He wants to conduct large-scale trials to show more conclusive results, but those require a substantial amount of funding. His research, he said, is only the tip of the iceberg.
Further research will surely reveal underlying biological mechanisms of action, will likely result in an array of therapeutic applications, and more importantly, because such experiences are foundationally related to our moral and our ethical understandings, further research may ultimately prove to be crucial to the very survival of our species, he said.
While Roland Griffiths became most well known for his study into the effects of psilocybin on patients with life-threatening cancer and death anxiety, he started his research on healthy patients. You can read the results of his cancer trial here.
The study on cancer patients showed more than 80 percent of participants experienced positive changes in attitudes about life, self, mood, relationships and spirituality, and many of them reported it was one of the most profound experiences of their lives, comparing it to the birth of a child. Studies on healthy participants also showed promising results with participants reporting similar effects. A high number of smokers quit smoking after participating in the study, he said on his TED Talk.
While the Johns Hopkins Medicine study on the effects of psilocybin showed very promising results in treating patients suffering from depression and anxiety related to life-threatening cancer diagnoses, the study only included 51 cancer patients.
Griffiths wants to conduct a much larger study, but that would require between $20 and $40 million. Without government funding, those funds would have to come from private donors or foundations, he told SciPol, a Duke University science and technology publication.
The larger study would be considered Phase 3. Multiple sites across the country would host studies including a much larger participant pool.
Ross, the NYU researcher, and Roland R. Griffiths, a professor of psychiatry and neurosciences at the Johns Hopkins medical school who led the study there, each said they would pursue a Phase 3 study enrolling a larger group of patients at multiple sites nationally, the publication said. That effort would take between $20 million and $40 million, and with government funding for a psychedelic research study unlikely, at least in the short term, that money would have to come from foundations and private donors.
The study involving Kerry Pappas and featured on 60 Minutes October 13, 2019 was Phase 2 of the study. It was led by the Heffter Research Institute and the RiverStyx Foundation, which are both non-profit organizations.
READ NEXT: Psilocybin: 5 Fast Facts You Need to Know
More:
Roland Griffiths: 5 Fast Facts You Need to Know - Heavy.com
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]